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mFor many physicians, the holy grail of prevention is
to identify thrombosis-prone “vulnerable” plaques
before they rupture or become destabilized. Several
observations underlie this quest. First, most heart
attacks occur in people with average levels of risk
factors who would not be considered eligible for
preventive treatment based on current guidelines.
One study (1) suggested that only 25% of patients
presenting with acute myocardial infarction (MI)
would have been identified as high-risk by the
National Cholesterol Education Program’s Adult
Treatment Panel III guidelines prior to the acute
event. Second, most MI originate from lesions that
are less severely narrowed. Several prospective and
See pages S76, S86, and S95
retrospective serial angiographic studies have re-
vealed that the culprit lesion in nearly two-thirds of
patients with acute coronary events had 50% to
70% diameter narrowing on coronary angiography
weeks or months prior to the index event (2–5).
Third, the site of myocardial ischemia during a
stress test—indicative of a hemodynamically signif-
icant “obstructive” stenosis—does not accurately
predict the site of future MI (6). Fourth, the
vulnerable plaques prone to rupture tend to expand
outside the vessel wall. Because of this “expansive
remodeling,” the lumen remains relatively uncom-
promised until the plaque has grown to a larger
volume (7–10). Thus, in most cases, these plaques
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
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Angeles, California. Both authors have reported that they have no
relationships relevant to the contents of this paper to disclose.re clinically silent before the “unheralded” acute
vent. Conventional angiography only detects ob-
tructive lesions, creating a need to develop alter-
atives for diagnosing the “nonobstructive” but
angerous culprit lesions. Fifth, in the past 2
ecades, invasive and noninvasive imaging tests
ave been developed that detect imaging character-
stics that correspond with the histological hall-
arks of vulnerable plaque identified on retrospec-
ive histopathological or autopsy studies (11). These
nclude a large lipid core (40% of total lesion
rea), a thin fibrous cap (65 m), and a rich
nflammatory infiltrate in the fibrous cap (12). The
vailability of these imaging tests has further fueled
nterest in the vulnerable plaque concept raising the
ossibility that prospective detection could lead to
re-emptive targeted therapeutic intervention,
hereby preventing the occurrence of many cardio-
ascular events.
In the past decade, several studies have evaluated
maging tools to characterize morphologic predic-
ors of plaque vulnerability (11). However, these
tudies are limited by their retrospective or cross-
ectional design (sampling only 1 point in time) and
mall sample size. In addition, neither the prognos-
ic utility (risk of future events caused by vulnerable
laques), nor the clinical utility (impact on physi-
ian decision making and/or patient outcomes) has
een prospectively validated (11). Furthermore, be-
ause these studies lacked prospective serial sam-
ling over a period of time during which athero-
hrombotic vascular events occur, it has not been
ossible to reliably document whether the identified
esions were directly responsible for future cardio-
ascular events. Thus, these studies are not infor-
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S107It is in this context that the results of the
PROSPECT (Providing Regional Observations to
Study Predictors of Events in the Coronary Tree)
trial provide the first glimpse into the natural
history of culprit lesion formation (13). Briefly, the
PROSPECT study examined 697 patients with
acute coronary syndromes. Following successful and
uncomplicated percutaneous coronary intervention
of culprit and other significant lesions, all patients
underwent angiography followed by grayscale and
adiofrequency intravascular ultrasonography (IVUS)
f the left main coronary artery and the proximal 6 to
cm of the 3 major coronary arteries to image the
onculprit lesions (NCL). After a median
ollow-up of 3.4 years, 135 patients experienced 149
ajor adverse cardiac events (MACE) reflecting a
-year cumulative rate of 20.4%. More than one-
alf of these events occurred within the first year.
hese patients underwent repeat angiography and
hrough comparisons with the earlier images, the
nvestigators could identify the earlier NCL that
ave rise to MACE. A total of 222 lesions were
udged to be related to MACE. Approximately
ne-half of these events and most of the severe
vents were judged to be related to the sites of the
riginal treated culprit lesions (118 lesions in 83
atients; 3-year cumulative event rate of 12.4%).
he remaining events, driven mostly by unstable or
rogressive angina requiring hospitalization, were
udged to be related to untreated NCL (104 lesions
n 74 patients; 3-year cumulative event rate of
1.6%). Although most of the NCL responsible for
ACE during follow-up were angiographically
ild (30% diameter stenosis), they were charac-
erized by IVUS as having a thin-cap fibroatheroma
TCFA), a large (70%) plaque burden (PB), a
mall (4.0 mm2) minimal luminal area (MLA), or
some combination of these. These findings are con-
sistent with the results of pathological studies (12).
The principal results of the PROSPECT study
were published earlier (13). In this issue of iJACC,
reports from 3 substudies (14–16) provide addi-
tional insights into plaque characteristics that pre-
dict clinical progression.
In the study by Brener et al. (14), the investiga-
tors examined whether the underlying atheroscle-
rotic disease burden as assessed by the presence or
absence of angiographically visible disease, defined
as 30% diameter stenosis (DS) by visual estima-
tion, is predictive of subsequent NCL-related
events. A total of 1,824 angiographically evident
NCL were observed with approximately 87% of
patients harboring at least 1 NCL. These pa- wtients—particularly those with multiple NCL (67%
of the cohort) and those with lesions 50% DS
(20% of the cohort)—were found to have a higher
rate of recurrent ischemic events over 3 years,
predominantly rehospitalization for severe progres-
sive or unstable angina requiring revascularization.
Patients with 1 NCL had greater frequency of
IVUS-defined plaque characteristics associated with
vulnerability. Of the 105 MACE-related NCL,
approximately one-third (n  32) originated from
angiographically more severe lesions (DS 50%),
whereas the remaining two-thirds originated from
angiographically mild (30% to 50% DS, n  41) or
nconspicuous (30% DS, n  32) lesions. How-
ever, the former were 4 as likely to result in
MACE than were the more prevalent milder NCL,
thereby confirming the greater lesion-specific risk
of events in angiographically more severe lesions.
Of the 1,824 NCL evaluated at baseline, only 73
(4%) contributed to future events, which is consis-
tent with previous observations that 5% of lesions
n individuals at risk progress to the culprit stage
17). Although the specificity of any given mild
esion to cause a future ischemic event was low, the
bsence of any angiographically evident NCL was
redictive of complete 3-year freedom from events
elated to untreated NCL, an important, favorable
rognostic signal.
In the study by Sanidas et al. (15), the investiga-
ors assessed whether substantial lesion progression
SLP), defined angiographically as 20% DS com-
ared with baseline, contributed to adverse cardiac
vents arising from NCL. Of the 72 patients in
hom MACE was judged to be related to NCL,
LP was observed in 44 patients (61%), suggesting
hat the process might underlie most, but not all,
CL-related events. Compared with NCL without
LP, lesions with SLP were less severe at baseline
ut more severe at the time of the event, indicating
ore rapid lesion progression. Despite being angio-
raphically less severe, NCL with SLP had a similar
laque burden as NCL without SLP, indicating
expansive remodeling” in the former. The 2 groups
id not differ significantly with respect to other
ngiographic or IVUS characteristics. Given the
ifferences in angiographic severity, it is not sur-
rising that the pattern of events as well as their
ime course differed among patients with NCL with
r without SLP. Whereas MI occurred only in
atients with NCL with SLP (presumably related
o increased circumferential stress in nonobstructive
esions leading to plaque destabilization), patients
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S108progressive angina (presumably due to higher num-
bers of obstructive flow-limiting lesions). Finally,
lesions with SLP presented with a delayed time
course consistent with the nonobstructive nature of
lesions at baseline. Of note, angiographic follow-up
was not performed in asymptomatic patients,
thereby precluding assessment of lesions that un-
derwent SLP without causing a clinical event.
Consequently, it is not possible to estimate the
impact of SLP on lesion-specific or patient-specific
risk of future MACE. However, because the 3-year
cumulative MACE rates were comparable for pa-
tients with (6.4%) and without (6.7%) SLP, it
indicates that SLP might not be an independent
predictor of MACE.
In the study by McPherson et al. (16), the
investigators evaluated the impact of residual PB as
assessed by IVUS on clinical progression. Of the
3,229 lesions evaluated, 288 were considered large
(i.e., PB 70%). At least 1 lesion with a PB 70%
as found in about one-third of patients (n 220).
hese lesions were associated with an increased
esion-specific, (8.7% vs. 1%) as well as patient-
pecific (20.8% vs. 7.7%) risk related to NCL, with
he percentage of PB found to be the strongest
ultivariable predictor of future lesion-specific
ACE. The risk was, however, primarily driven by
ncreased rates of unstable or progressive angina.
Data Summary
Table 1 summarizes the prognostic performance of
different plaque characteristics based on the data
from these 3 reports as well as the original pub-
rformance of Plaque Characteristics
Endpoint
Event Rate, % (n/N)*
 Lesion Variable  Lesion Variab
NCL MACE 8.7% (25/288) 1.0% (30/2941
NCL MACE 4.9% (30/616) 1.0% (25/2522
NCL MACE 4.4% (26/595) 1.2% (25/2114
4.0 mm2 NCL MACE 18.2% (8/44) 1.6% (43/2665
NCL MACE 10.7% (36/336) 2.5% (37/1488
)
CL  NCL MACE 20.7% (125/604) 7.5% (7/93)
NCL MACE 12.3% (74/604) 0% (0/93)
NCL MACE 19.1% (42/220) 7.0% (31/440)
eciﬁc risk estimates for SLP and NCL, and patient-speciﬁc risk estimates for MLA,
.
eiver-operator curve; CI  conﬁdence interval; CL  culprit lesion; DS  diameter st
minimum luminal area; NCL nonculprit lesion; NPV negative predictive value
speciﬁcity; SLP  substantial lesion progression; TCFA  thin-cap ﬁbroatheroma.lished report. Measures used to judge the prognos-
tic utility include the strength of association or
effect size (odds ratios), classification performance
measures traditionally used for evaluation of diag-
nostic tests such as sensitivity, specificity, likelihood
ratio, and predictive accuracy (positive and negative
predictive value), and discrimination measure using
the area under the receiver operating-characteristic
curve (AUC). Lesion-specific as well as patient-
specific risk estimates are reported.
For lesion-specific estimates, the strength of
association varied from an odds ratio of 3.82 for
TCFA to 9.55 for PB 70%; sensitivity ranged
from 46% for PB 70% to 55% for MLA 4.0
m2; specificity from 79% for TCFA to 92% for
PB 70%. With the exception of PB 70%, likeli-
hood ratios (LR) were all in the small to modest range
(5 for LR or 0.5 for LR–). Although all lesion
haracteristics were significantly associated with out-
omes, the positive predictive value ranged from 4% to
1%, reflecting the low prevalence (pre-test likelihood)
f outcomes. The C index as measured by AUC tracked
ith other risk estimates with PB 70% yielding the
ighest discrimination (AUC 0.82). Lesions exhib-
ting all 3 IVUS-defined correlates of vulnerability
PB 70%  MLA 4.0 mm2  TCFA) yielded
the highest odds ratio, specificity, LR, and AUC, as
well as the least sensitivity and LR– for predicting
future NCL-related events. However, the positive
predictive value was only 18%, reflecting the low
prevalence of MACE outcomes.
With regard to patient-specific estimates, the pres-
ence of angiographically evident NCL (DS 30%)
OR* Sn Sp PPV NPV LR LR AUC (95% CI)
9.55 0.46 0.92 9% 99% 5.59 0.59 0.82 (0.76–0.87)
5.11 0.55 0.81 5% 99% 2.87 0.56 0.75 (0.67–0.82)
3.82 0.51 0.79 4% 99% 2.38 0.62 0.71 (0.62–0.79)
13.55 0.16 0.99 18% 98% 11.58 0.85 0.86 (0.76–0.92)
4.71 0.49 0.83 11% 98% 2.88 0.61 0.74 (0.67–0.80)
3.2 0.95 0.15 21% 92% 1.12 0.35 0.69 (0.56–0.79)
NR 1.00 0.15 12% 100% 1.18 0.00 NR
3.11 0.58 0.70 19% 93% 1.90 0.61 0.68 (0.60–0.75)
, and DS 50% were not available. *Event rates and odds ratios are not based
s; LR–  negative likelihood ratio; LR  positive likelihood ratio; MACE  major
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S109yielded the highest sensitivity (95% for all culprit and
NCL MACE and 100% for only NCL MACE) and
LR– (0.35 and 0), but also the lowest specificity (15%)
and LR (1.1 and 1.18). The positive predictive value
as modest (12% and 21%) although negative predic-
ive value for NCL MACE was 100%; discrimination
as modest for MACE related to both culprit and
onculprit lesions. Risk discrimination was compara-
ly modest for PB70%. Patient-specific risk related
o MLA, TCFA, or DS 50% could not be esti-
ated because required data were not reported.
From these data, we conclude that large plaque
urden (PB 70%), alone or in combination with
ther lesion characteristics, is relatively highly pre-
ictive for future NCL-related MACE compared
ith other plaque characteristics. This is consistent
ith the observation that these lesions are more
ikely to progress, compromise lumen, and become
ow-limiting, eventually resulting in ischemic
ymptoms. Although these lesions were highly pre-
ictive of future events, they contributed to less
han one-half the number of NCL-related events
25 of 55) simply because they were far outnum-
ered by a factor of 10 by less severe lesions (288 vs.
,941).
Table 2 shows the prognostic utility of 2 patient-
elated variables that were found to be independent
orrelates of MACE related to NCL (13). Notably,
he discriminant value for patient-specific risk for
oth these variables was comparable to the lesion-
ased variables, thereby raising questions regarding
he incremental predictive utility of the latter.
Modest Prognostic Utility
There are several reasons to account for the rather
modest prognostic utility of vulnerable plaque char-
acteristics identified by IVUS in the PROSPECT
study. First, IVUS resolution of 100 to 150 m is
far from adequate for precise evaluation of the
plaque characteristics. Second, plaques frequently
evolve from low-risk phenotype (thick cap fibro-
atheroma) to high-risk phenotype (TCFA) over
time. Without repeat IVUS evaluation at the time
of the recurrent event, such dynamic transition in
Table 2. Predictive Performance of Patient Characteristics
Endpoint
Event Rate, % (n/N)*
 Variable – Variab
Insulin-requiring diabetes NCL MACE 28.6% (6/21) 10.5% (70/
Previous PCI NCL MACE 20.0% (15/75) 9.95% (61/
*Event rates and odds ratios are not based on Kaplan-Meier estimates.
PCI  percutaneous coronary intervention; other abbreviations as in Table 1.plaque morphology prior to rupture might have
been missed. Third, imaging characteristics such as
TCFA have not been validated as reliable surro-
gates for histological markers of plaque vulnerabil-
ity. No correlation between necrotic core size de-
termined by real and virtual histology was found in
a recent histopathological study in porcine coronary
arteries, thereby questioning the role of IVUS in
detection of TCFA (18). Fourth, inflammatory cell
infiltrate, a hallmark of vulnerable plaque, cannot be
detected by IVUS. Fifth, not all plaques that
rupture actually result in a clinical cardiovascular
event. Some plaques rupture and then become
quiescent and heal without causing MI or ischemic
symptoms (so-called silent plaque rupture). Con-
versely, not all acute cardiovascular events are the
result of plaque rupture because nonruptured
plaques have been implicated as culprit lesions
nearly one-third of the time in autopsy series (19).
Sixth, approximately one-half of the future culprit
lesions were located in distal vessels inaccessible to
IVUS. Finally, aggressive secondary prevention
treatment instituted in the PROSPECT study
might have mitigated the risk of plaque rupture
resulting in too few “hard” clinical events (cardiac
death or MI) to assess reliably the prognostic utility
of vulnerable plaque.
Implications
Adoption of IVUS-based methods for detection of
plaque vulnerability in clinical practice should ide-
ally be predicated on 3 principles: 1) prospective
validation of IVUS-defined plaque characteristics as
an independent predictor of future cardiovascular
event; 2) establishment of incremental predictive
utility (preferably based on change in discrimination
or risk classification) on top of currently available
less expensive or less invasive methods of risk
stratification; and 3) demonstration that detection
would alter treatment decisions leading to improved
outcomes in a cost-effective manner. It is debatable
if IVUS (or for that matter any other imaging tool)
fulfills these criteria. Even if an imaging tool were
shown to be endowed with these desirable attri-
OR* Sn Sp PPV NPV LR LR AUC (95% CI)
) 3.40 0.08 0.98 29% 89% 3.21 0.94 0.69 (0.53–0.82)
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S110butes, the positive predictive value of plaque vul-
nerability will be constrained by the prevalence or
pre-test probability of cardiovascular disease in the
screened population, thereby making it less feasible
in primary prevention compared with secondary
prevention settings. Other lingering questions re-
main about these imaging tools. Can pre-emptive,
focal treatment of invasively detected vulnerable
plaques be accomplished in a safe, efficacious, and
cost-effective manner? Should systemic secondary
prevention strategies be tailored (scaled up or down)
on the detection of vulnerable plaques? Such ques-
tions will need to be answered before detection of
vulnerable plaque by IVUS (or any other invasive or7. Schoenhagen P, Ziada KM, Kapadia







mild lesions in acprevention and treatment of cardiovascular disease.
In the meantime, the best we can hope is that
insights gained from studies such as PROSPECT
will continue to provide a strong impetus for con-
tinued basic research in how plaques progress,
which may help identify new therapeutic targets to
prevent the deadly minority of atherosclerotic le-
sions that trigger the leading cause of death world-
wide (20).
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